You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?

Article Text

Article menu

Download PDFPDF

Spondyloarthritis
Original article
Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?
  1. Anne Sofie Siebuhr1,
  2. Desirée van der Heijde2,
  3. Anne-C Bay-Jensen1,
  4. Morten Asser Karsdal1,
  5. Robert Landewé3,4,
  6. Astrid van Tubergen5 and
  7. Sofia Ramiro2
  1. 1Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
  2. 2Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  3. 3Amsterdam Rheumatology Center, Amsterdam, The Netherlands
  4. 4Medical Center, Heerlen, The Netherlands
  5. 5Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and CAPHRI-School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands
  1. Correspondence to Dr Anne Sofie Siebuhr, Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark; aso{at}nordicbio.com

Abstract

Background Radiographic axial spondyloarthritis (r-axSpA) is associated with extracellular matrix (ECM) remodelling of affected tissues. We investigated whether there was a relationship between biomarkers of ECM remodelling and 2-year radiographic progression in r-axSpA.

Methods Patients from the Outcome in Ankylosing Spondylitis International Study (OASIS) were included if they had serum, clinical and spinal radiographic assessments available at baseline and 2 years later. Two readers independently scored the radiographs according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). The average score was used. Type I, V and VI collagen metabolites (C1M, C5M and C6M) and citrullinated and matrix metalloproteinase-degraded vimentin (VICM) were assessed in serum by ELISAs. The relationship between serum biomarkers and 2-year radiographic progression was investigated using linear regression analyses adjusted for potential confounders. Interactions were tested.

Results Patients included (n=122) had a mean age of 45 years (SD 12), 70% were male and 82% were human leucocyte antigen-B27 positive. The mean 2-year mSASSS progression was 2.1 (2.9) units. Only C1M was significantly associated with mSASSS progression (β=0.01, 95% CI 0.00 to 0.03). The effect disappeared after adjustment for confounders. C5M, C6M and VICM showed no relationship with mSASSS progression.

Conclusion We did not find evidence that degradation of ECM is related to radiographic progression in patients with r-axSpA.

  • ankylosing spondylitis
  • outcomes research
  • smoking
  • spondyloarthritis

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/rmdopen-2018-000648

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors All authors have planned and designed the biomarker study. ASS did the biomarker assessment. All authors were involved in the data analysis, scientific discussion and interpretation of the data. Additionally, all authors were involved with drafting the manuscript, approving the manuscript prior to submission and have agreed to be accountable for all published data.

    • Funding The work was supported by The Danish Research Foundation.

    • Competing interests MAK and A-CB-J are full-time employees and shareholder in Nordic Bioscience. ASS is full-time employee of Nordic Bioscience.

    • Patient consent Not required.

    • Ethics approval Local ethics committee at the Maastricht University Medical Centre.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement Availability of data and material: the data set used and analysed during the current study is available from the corresponding author on reasonable request.

    • Presented at These data have been presented as an abstract at the EULAR congress in 2014.